N. Taghavi, F. Mashhadiabbas, Parisa Kardouni, F. Aghdashi
Metastasis to maxillofacial region is extremely rare and constitutes less than 1% of all oral malignancies. The mandible is thepreferred site. Here, we describe the case of an 82-year-old male with mandibular metastasis from prostate carcinoma and reviewof 10 reported cases in the English literature up to 2016.
{"title":"Mandibular metastasis from a prostate adenocarcinoma: Report a case and review of the literature","authors":"N. Taghavi, F. Mashhadiabbas, Parisa Kardouni, F. Aghdashi","doi":"10.5430/JST.V6N1P91","DOIUrl":"https://doi.org/10.5430/JST.V6N1P91","url":null,"abstract":"Metastasis to maxillofacial region is extremely rare and constitutes less than 1% of all oral malignancies. The mandible is thepreferred site. Here, we describe the case of an 82-year-old male with mandibular metastasis from prostate carcinoma and reviewof 10 reported cases in the English literature up to 2016.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"13 1","pages":"91-93"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78470350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexander H. Jinnah, Shadi A. Qasem, Cynthia L. Emory
Erdheim Chester Disease (ECD) is characterized by organ infiltration by CD68 positive and CD1a negative non-LangerhansHistiocytes. The presentation of ECD can vary from bone pain due to bone infiltration to multi-systemic forms involving thecardiovascular system. The prognosis of ECD is poor; however, with increased understanding of the pathogenesis, this has led tothe evolution of new therapeutic strategies. Because of the increased need for understanding this disease we present a case of a man, who presented to us with bone painand radiographs showing a lytic lesion in his left femur. Upon further investigation with magnetic resonance (MR) imaging andtechnetium 99 m bone scan we chose to undergo an open biopsy, which led to the definitive diagnosis. We outline the currenttreatment regimen and its evolution as our understanding of the pathogenesis of ECD has increased.
{"title":"Erdheim chester disease presenting as bone pain with a lytic lesion: Case history and review of the literature","authors":"Alexander H. Jinnah, Shadi A. Qasem, Cynthia L. Emory","doi":"10.5430/JST.V6N1P87","DOIUrl":"https://doi.org/10.5430/JST.V6N1P87","url":null,"abstract":"Erdheim Chester Disease (ECD) is characterized by organ infiltration by CD68 positive and CD1a negative non-LangerhansHistiocytes. The presentation of ECD can vary from bone pain due to bone infiltration to multi-systemic forms involving thecardiovascular system. The prognosis of ECD is poor; however, with increased understanding of the pathogenesis, this has led tothe evolution of new therapeutic strategies. Because of the increased need for understanding this disease we present a case of a man, who presented to us with bone painand radiographs showing a lytic lesion in his left femur. Upon further investigation with magnetic resonance (MR) imaging andtechnetium 99 m bone scan we chose to undergo an open biopsy, which led to the definitive diagnosis. We outline the currenttreatment regimen and its evolution as our understanding of the pathogenesis of ECD has increased.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"7 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2016-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91123408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: MicroRNAs (miRNAs) are small noncoding RNAs that typically inhibit translation and stability of messengerRNAs (mRNAs) and as such control expression of genes involved in different cellular processes. Several miRNAs have beenlinked to cancer and immune cells but whether there is a correlation between their expressions in both cells is still indistinct. Aim: In this study, we aimed to analyze miRNAs in tumor and immune cells in tumor bearing mice treated with or withoutchemotherapy. Methods: CD1 mice were inoculated with intraperitoneal (i.p.) injection of 106 viable cells from Ehrlich ascetic carcinoma (EAC)cell line to form ascities. Mice were then i.p. treated with PBS ascontrol or with cispaltin (10 or 40 μg/mouse). Semiquantificationof miRNAs 146a and 155 in spleen and tumor cells was done after 1 or 2 weeks of treatments using RT-PCR. Results: The transcription level of miRNA-146a decreased in EAC and spleen cells, while miRNA-155 expression level increased.In EAC-bearing mice treated with CIS for 1 week, miRNA-155 expression level considerably increased in spleen and tumor cellsas compared to tumor-non-bearing and untreated tumor-bearing mice. In contrast, the miRNA-146a transcription level decreasedin both spleen and tumor cells as compared to its expression level in naive and untreated EAC- bearing mice. Two weeks postCIS treatment of EAC-bearing mice, spleen cells still show low expression levels of miRNA-146a, while theexpression levels ofmiRNA-155 increased in both spleen and tumor cells. Taken together, these results suggest that miRNA expression is significantlyaltered by tumor progression and by chemotherapy.
{"title":"Tumor burden and cisplatin treatment alters the expression levels of microRNA-146a and -155 in spleen and cancer cells in an experimental mouse model of Ehrlich ascite carcinoma","authors":"M. Salem, S. Kholy, Afaf Al-Atrash, Duaa Samy","doi":"10.5430/JST.V6N1P78","DOIUrl":"https://doi.org/10.5430/JST.V6N1P78","url":null,"abstract":"Background: MicroRNAs (miRNAs) are small noncoding RNAs that typically inhibit translation and stability of messengerRNAs (mRNAs) and as such control expression of genes involved in different cellular processes. Several miRNAs have beenlinked to cancer and immune cells but whether there is a correlation between their expressions in both cells is still indistinct. Aim: In this study, we aimed to analyze miRNAs in tumor and immune cells in tumor bearing mice treated with or withoutchemotherapy. Methods: CD1 mice were inoculated with intraperitoneal (i.p.) injection of 106 viable cells from Ehrlich ascetic carcinoma (EAC)cell line to form ascities. Mice were then i.p. treated with PBS ascontrol or with cispaltin (10 or 40 μg/mouse). Semiquantificationof miRNAs 146a and 155 in spleen and tumor cells was done after 1 or 2 weeks of treatments using RT-PCR. Results: The transcription level of miRNA-146a decreased in EAC and spleen cells, while miRNA-155 expression level increased.In EAC-bearing mice treated with CIS for 1 week, miRNA-155 expression level considerably increased in spleen and tumor cellsas compared to tumor-non-bearing and untreated tumor-bearing mice. In contrast, the miRNA-146a transcription level decreasedin both spleen and tumor cells as compared to its expression level in naive and untreated EAC- bearing mice. Two weeks postCIS treatment of EAC-bearing mice, spleen cells still show low expression levels of miRNA-146a, while theexpression levels ofmiRNA-155 increased in both spleen and tumor cells. Taken together, these results suggest that miRNA expression is significantlyaltered by tumor progression and by chemotherapy.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"os-14 1","pages":"78"},"PeriodicalIF":0.0,"publicationDate":"2016-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87388733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor mass that grows and metastasizes rapidly. There are no definitivemethods for early detection and most patients are diagnosed at a late stage. Those diagnosed at an early stage are eligible for tumorresection. However, many of these patients are soon burdened with tumor recurrence. The tumor grows back aggressively andwith resistance to the original chemotherapy. Gemcitabine has been the treatment of choice, but provides only minimal survivalprolongation. Researchers are trying to improve the current standard of care by finding different methods to improve treatmentefficacy and reduce side effects. This review emphasizes recent data on targeting the tumor using antifibrotic, nanotargeted, anddendritic cell therapies. Antifibrotic therapy aims to reduce tumor fibrosis, which prevents adequate chemotherapy penetration.Nanotargeted therapy offers precise targeting of cancer cells and chemotherapy delivery. Dendritic cell vaccines stimulate thebody’s immune system to target PDAC cells. These three treatment methods or a combination of them might improve the lifespanand quality of life for PDAC patients.
{"title":"Emerging therapies for pancreatic ductal carcinoma","authors":"R. Falcone, P. Davis, S. Stain, S. Mousa","doi":"10.5430/JST.V6N1P65","DOIUrl":"https://doi.org/10.5430/JST.V6N1P65","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor mass that grows and metastasizes rapidly. There are no definitivemethods for early detection and most patients are diagnosed at a late stage. Those diagnosed at an early stage are eligible for tumorresection. However, many of these patients are soon burdened with tumor recurrence. The tumor grows back aggressively andwith resistance to the original chemotherapy. Gemcitabine has been the treatment of choice, but provides only minimal survivalprolongation. Researchers are trying to improve the current standard of care by finding different methods to improve treatmentefficacy and reduce side effects. This review emphasizes recent data on targeting the tumor using antifibrotic, nanotargeted, anddendritic cell therapies. Antifibrotic therapy aims to reduce tumor fibrosis, which prevents adequate chemotherapy penetration.Nanotargeted therapy offers precise targeting of cancer cells and chemotherapy delivery. Dendritic cell vaccines stimulate thebody’s immune system to target PDAC cells. These three treatment methods or a combination of them might improve the lifespanand quality of life for PDAC patients.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"13 1","pages":"65"},"PeriodicalIF":0.0,"publicationDate":"2016-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82965500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Belliraj, S. Rabiou, I. I. Alzouma, J. Ghalimi, F. Ammor, M. Lakranbi, Y. Ouadnouni, M. Smahi
Leiomyosarcoma is a malignant tumor of smooth muscle, primitive pleural localization is extremely rare, to our knowledge onlyten cases have been reported in the literature. The prognosis is usually grim, the survival of patients with extensive disease isabout 12 months. Our patient has survived 42 months which is rarely reported in the literature.
{"title":"Primitive pleural leiomyosarcoma: Case report","authors":"L. Belliraj, S. Rabiou, I. I. Alzouma, J. Ghalimi, F. Ammor, M. Lakranbi, Y. Ouadnouni, M. Smahi","doi":"10.5430/JST.V6N1P62","DOIUrl":"https://doi.org/10.5430/JST.V6N1P62","url":null,"abstract":"Leiomyosarcoma is a malignant tumor of smooth muscle, primitive pleural localization is extremely rare, to our knowledge onlyten cases have been reported in the literature. The prognosis is usually grim, the survival of patients with extensive disease isabout 12 months. Our patient has survived 42 months which is rarely reported in the literature.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"2 1","pages":"62"},"PeriodicalIF":0.0,"publicationDate":"2016-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89905971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tuberous sclerosis complex (TSC) is a multi-system disorder with autosomal dominant inheritance, which can affect the brain,heart, skin, kidneys, lungs, and retina. We present an obsessive-compulsive disorder patient, with classic dermatological findingsand subependymal giant cell astrocytoma in TSC.
{"title":"Obsessive compulsive disorder in a patient with tuberous sclerosis and subependymal giant cell astrocytoma","authors":"G. Haddad, F. Romero, H. Miot","doi":"10.5430/JST.V6N1P59","DOIUrl":"https://doi.org/10.5430/JST.V6N1P59","url":null,"abstract":"Tuberous sclerosis complex (TSC) is a multi-system disorder with autosomal dominant inheritance, which can affect the brain,heart, skin, kidneys, lungs, and retina. We present an obsessive-compulsive disorder patient, with classic dermatological findingsand subependymal giant cell astrocytoma in TSC.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"49 1 1","pages":"59"},"PeriodicalIF":0.0,"publicationDate":"2016-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89605545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Malignant pleural mesothelioma (MPM) is a rare but very aggressive neoplasm. Prognosis is poor and the disease is fatalwithin 4-8 months without treatment. Even with a trimodality treatment approach, which has been shown to produce significantmorbidity, median survival does not exceed 11 months. There is a need therefore for exploring new treatment options that canimprove both qualitative and quantitative outcomes. This case report describes locally advanced malignant pleural mesothelioma treated with a unique, customized irradiationtechnique involving a combination of 3D conformal therapy and intensity modulated radiotherapy (IMRT). This allowed fortreatment of the pleura to a high dose, while sparing the lung parenchyma. In this patient, our approach resulted in a prolongedremission. It is our hope that this stimulates new interest in the use of modern day radiation techniques in the treatment of MPM.
{"title":"Contemporary radiation therapy techniques in malignant pleural mesothelioma: A case report","authors":"J. Halpern, S. McVorran, M. Loksen","doi":"10.5430/JST.V6N1P54","DOIUrl":"https://doi.org/10.5430/JST.V6N1P54","url":null,"abstract":"Malignant pleural mesothelioma (MPM) is a rare but very aggressive neoplasm. Prognosis is poor and the disease is fatalwithin 4-8 months without treatment. Even with a trimodality treatment approach, which has been shown to produce significantmorbidity, median survival does not exceed 11 months. There is a need therefore for exploring new treatment options that canimprove both qualitative and quantitative outcomes. This case report describes locally advanced malignant pleural mesothelioma treated with a unique, customized irradiationtechnique involving a combination of 3D conformal therapy and intensity modulated radiotherapy (IMRT). This allowed fortreatment of the pleura to a high dose, while sparing the lung parenchyma. In this patient, our approach resulted in a prolongedremission. It is our hope that this stimulates new interest in the use of modern day radiation techniques in the treatment of MPM.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"8 1","pages":"54"},"PeriodicalIF":0.0,"publicationDate":"2015-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89433380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlo Ciulla, D. Veljanovski, U. Shikoska, Filip A. Risteski
Objective: This paper expands on the basis of previous research confirming through empirical evidence both meaning and natureof the classic-curvature and the intensity-curvature functional images. Methods: Eleven subjects affected by human brain tumors were scanned using Magnetic Resonance Imaging (MRI). TwodimensionalMRI images were selected to study the subjects using the intensity-curvature measurement approaches called:classic-curvature and intensity-curvature functional. The bivariate cubic polynomial and the bivariate linear function were fittedto the MRI images in order to compute the classic-curvature and the intensity-curvature functional respectively. Results: This work shows one novelty related to the use of the two intensity-curvature measurement approaches when furtheringthe study of tumors detected with MRI. The novelty is the highlight of the accumulation of the contrast agent through the visuallyperceptible third dimension perpendicular to the imaging plane. Conclusions: The meaning and the nature of the aforementioned intensity-curvature measurement approaches is the capability tofilter the MRI.
{"title":"On the properties of the intensity-curvature measurement approaches: the classic-curvature and the intensity-curvature functional","authors":"Carlo Ciulla, D. Veljanovski, U. Shikoska, Filip A. Risteski","doi":"10.5430/JST.V6N1P38","DOIUrl":"https://doi.org/10.5430/JST.V6N1P38","url":null,"abstract":"Objective: This paper expands on the basis of previous research confirming through empirical evidence both meaning and natureof the classic-curvature and the intensity-curvature functional images. Methods: Eleven subjects affected by human brain tumors were scanned using Magnetic Resonance Imaging (MRI). TwodimensionalMRI images were selected to study the subjects using the intensity-curvature measurement approaches called:classic-curvature and intensity-curvature functional. The bivariate cubic polynomial and the bivariate linear function were fittedto the MRI images in order to compute the classic-curvature and the intensity-curvature functional respectively. Results: This work shows one novelty related to the use of the two intensity-curvature measurement approaches when furtheringthe study of tumors detected with MRI. The novelty is the highlight of the accumulation of the contrast agent through the visuallyperceptible third dimension perpendicular to the imaging plane. Conclusions: The meaning and the nature of the aforementioned intensity-curvature measurement approaches is the capability tofilter the MRI.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"38 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2015-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85468995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rationale: Epithelial ovarian cancer (EOC) is a relatively chemosensitive malignancy which begins, and most frequentlydisseminates by intraperitoneal seeding. Intraperitoneal chemotherapy (IP) is a route of drug delivery that allows the directinfusion of the chemotherapeutic agents into the peritoneal cavity. It has been proven to be efficient and with lower systemic sideeffects in comparison to the intravenous (IV) route. The combination between hyperthermia and intraperitoneal chemotherapy(Hyperthermic intraperitoneal chemotherapy) has a synergistic killing effect on the malignant cells and appears to be feasible inthe treatment of EOC. Objective: To review the current literature and discuss the use of HIPEC in the course of the EOC treatment: as first line medicaltreatment, at the time of cytoreductive surgery (CS), postoperative adjuvant IP chemotherapy and HIPEC, and for recurrentdisease focusing on the survival benefit, mortality rates, morbidity, adverse effects and limitations. Method: Medline, Pubmed, and the Cochrane Central Register of Controlled Trials (CENTRAL ) were investigated for Englishlanguage articles about the role of HIPEC in women with primary EOC, of any FIGO stage. The analysis was restricted toretrospective studies, randomized and nonrandomized controlled clinical trials, and gynecological oncology journals. The selectedinformation included data on feasibility, overall survival (OS), quality of life, and comparison with standard IV chemotherapy interms of complications, toxicity and anticancer effects. Conclusion: Hyperthermia of the IP chemotherapy solution increases the cytotoxicity of the drug in the peritoneal cavity andits systemic effects on the tumor peritoneal nodules. Although initial investigators presented encouraging survival outcomeswhen HIPEC was used in recurrent EOC, further studies are necessary in order to incorporate HIPEC as a front-line treatmentof EOC or as an adjuvant therapy. More research is required for defining the possible roles of HIPEC within the spectrum ofother treatments for EOC including repeated normothermic IP chemotherapy, early postoperative IP chemotherapy, and novel andbiological agents.
{"title":"Should we use the hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer? A literature review","authors":"N. Bacalbaşa, O. Ionescu, I. Bălescu","doi":"10.5430/JST.V6N1P21","DOIUrl":"https://doi.org/10.5430/JST.V6N1P21","url":null,"abstract":"Rationale: Epithelial ovarian cancer (EOC) is a relatively chemosensitive malignancy which begins, and most frequentlydisseminates by intraperitoneal seeding. Intraperitoneal chemotherapy (IP) is a route of drug delivery that allows the directinfusion of the chemotherapeutic agents into the peritoneal cavity. It has been proven to be efficient and with lower systemic sideeffects in comparison to the intravenous (IV) route. The combination between hyperthermia and intraperitoneal chemotherapy(Hyperthermic intraperitoneal chemotherapy) has a synergistic killing effect on the malignant cells and appears to be feasible inthe treatment of EOC. Objective: To review the current literature and discuss the use of HIPEC in the course of the EOC treatment: as first line medicaltreatment, at the time of cytoreductive surgery (CS), postoperative adjuvant IP chemotherapy and HIPEC, and for recurrentdisease focusing on the survival benefit, mortality rates, morbidity, adverse effects and limitations. Method: Medline, Pubmed, and the Cochrane Central Register of Controlled Trials (CENTRAL ) were investigated for Englishlanguage articles about the role of HIPEC in women with primary EOC, of any FIGO stage. The analysis was restricted toretrospective studies, randomized and nonrandomized controlled clinical trials, and gynecological oncology journals. The selectedinformation included data on feasibility, overall survival (OS), quality of life, and comparison with standard IV chemotherapy interms of complications, toxicity and anticancer effects. Conclusion: Hyperthermia of the IP chemotherapy solution increases the cytotoxicity of the drug in the peritoneal cavity andits systemic effects on the tumor peritoneal nodules. Although initial investigators presented encouraging survival outcomeswhen HIPEC was used in recurrent EOC, further studies are necessary in order to incorporate HIPEC as a front-line treatmentof EOC or as an adjuvant therapy. More research is required for defining the possible roles of HIPEC within the spectrum ofother treatments for EOC including repeated normothermic IP chemotherapy, early postoperative IP chemotherapy, and novel andbiological agents.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"180 1","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2015-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85554317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Primary malignant cartilaginous tumors of the lung are rare with limited reports in the literature. Here we describe the case of a69-year-old male who presented with a lobulated left upper lobe mass. Preoperative percutaneous biopsy was consistent with amucinous adenocarcinoma. Final pathology demonstrated a primary extraskeletal pulmonary myxoid chrondrosarcoma. Theclinical presentation and histologic characteristics are described.
{"title":"A rare case of extraskeletal pulmonary myxoid chondrosarcoma","authors":"K. Endicott, S. Barak, K. Mortman","doi":"10.5430/JST.V6N1P18","DOIUrl":"https://doi.org/10.5430/JST.V6N1P18","url":null,"abstract":"Primary malignant cartilaginous tumors of the lung are rare with limited reports in the literature. Here we describe the case of a69-year-old male who presented with a lobulated left upper lobe mass. Preoperative percutaneous biopsy was consistent with amucinous adenocarcinoma. Final pathology demonstrated a primary extraskeletal pulmonary myxoid chrondrosarcoma. Theclinical presentation and histologic characteristics are described.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"11 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2015-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77764341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：